Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 42Leukemia 34Lymphoma, Large B-Cell, Diffuse 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia, Myeloid, Acute 24Burkitt Lymphoma 19Leukemia, Myelomonocytic, Acute 16Lung Neoplasms 15Leukemia, Monocytic, Acute 15Neuroblastoma 14Leukemia, Megakaryoblastic, Acute 14Leukemia, Erythroblastic, Acute 14Lymphoma, Non-Hodgkin 13Lymphoma, Follicular 13Hodgkin Disease 12Congenital Abnormalities 12Carcinoma, Non-Small-Cell Lung 12Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, Mantle-Cell 10Central Nervous System Neoplasms 10Sarcoma 9Myelodysplastic Syndromes 9Anemia, Refractory, with Excess of Blasts 8Small Cell Lung Carcinoma 7Myeloproliferative Disorders 7Leukemia, Myelomonocytic, Chronic 7Leukemia, Lymphocytic, Chronic, B-Cell 7Testicular Neoplasms 6Multiple Myeloma 6Lymphoma, B-Cell, Marginal Zone 6

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Etoposide × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡